DEINOVE (Euronext Growth Paris: ALDEI), a French biotechnology company pioneering the study and exploitation of bacterial biodiversity to address the urgent and global challenge of antimicrobial resistance, announces that it today declared and applied for the suspension of payments to the Montpellier Commercial Court the opening of insolvency proceedings.

The employee representatives were informed in advance.

The purpose of this procedure is to evaluate all the solutions that allow, under the best conditions, to continue the activity, maintain employment and settle the debts, as well as to start a process of looking for investors as part of a recovery plan continuation or a divestment plan.

Mining will continue throughout the observation period.

The company will inform the market about the decision of the commercial court of Montpellier.

Under these conditions, DEINOVE had asked Euronext to suspend the listing of its share (ISIN: FR0010879056) on Euronext Growth as of October 28, before the market opens, pending the publication of a press release and until further notice. Given the uncertainty about the outcome of the measures taken by the company, the suspension of the listing of the company’s shares (ISIN: FR0010879056) is maintained until further notice.

to PROPOSALS DE DEINOVE

DEINOVE is a French biotechnology company pioneering in unlocking a 99.9% unexplored area of ??life: “microbial dark matter”. By uncovering the metabolic potential of rare or previously uncultivable bacteria, she addresses a global public health and economic challenge: antibiotic resistance.

The news…